Across TCGA pan-cancer cohorts, SBK3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SBK3 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher SBK3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SBK3 expression acts as an unfavorable survival marker.
SCLC are the cancer types where SBK3 Mutation most reproducibly stratifies survival.